The authors declare that they do not have any potential conflict of interest.
Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status
Article first published online: 9 NOV 2012
© 2012 Wiley Periodicals, Inc.
Special Issue: Genetic Susceptibility to Cancer in Diverse Populations
Volume 52, Issue S1, pages 52–59, November 2013
How to Cite
Cen, Y.-L., Qi, M.-L., Li, H.-G., Su, Y., Chen, L.-J., Lin, Y., Chen, W.-Q., Xie, X.-M., Tang, L.-Y. and Ren, Z.-F. (2013), Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol. Carcinog., 52: 52–59. doi: 10.1002/mc.21979
Yu-Ling Cen and Mei-Ling Qi contributed equally to this work.
- Issue published online: 24 OCT 2013
- Article first published online: 9 NOV 2012
- Manuscript Accepted: 18 OCT 2012
- Manuscript Revised: 8 OCT 2012
- Manuscript Received: 22 MAY 2012
- National Natural Science Foundation of China. Grant Numbers: 81072383, 81273147, 81172759
- Fundamental Research Funds for the Central Universities of China. Grant Number: 10ykjc24
- breast cancer;
- fibroblast growth factor 1;
- RNA binding protein fox-1 homolog 2;
- fibroblast growth factor receptor 2;
Genetic polymorphisms of fibroblast growth factor receptor 2 (FGFR2) have been demonstrated to be associated with breast cancer risk, presumably through elevation of FGFR2 expression. Fibroblast growth factor 1 (FGF1) and RNA binding protein fox-1 homolog 2 (RBFOX2), which are functionally related to FGFR2, may also associate with breast cancer risk. We investigated the associations between breast cancer risk and the polymorphisms of FGFR2 rs2981582, FGF1 rs250108, and RBFOX2 rs2051579 among 839 incident breast cancer cases and 863 age-matched controls in the Guangzhou Breast Cancer Study. Stratified odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by estrogen receptor (ER)/progesterone receptor (PR) status using multivariate logistic regression. FGFR2 rs2981582 was confirmed to be significantly associated with the risk of ER-positive but not ER-negative breast cancer. In contrast, FGF1 rs250108 was significantly associated with the risk of ER-negative breast cancer (OR (95% CI) = 1.68 (1.20–2.35) for CT + TT vs. CC genotype) but not ER-positive breast cancer. CA + AA genotypes at RBFOX2 rs2051579 were associated with a reduced risk of ER-negative (0.71 (0.52–0.97)) but not ER-positive breast cancer compared to the CC genotype. Similar results were observed when differentiating breast cancer cases by PR status. Neither of the pairs between the three SNPs had a significant interaction on breast cancer risk. Our findings show a suggestively stronger association between FGFR2 rs2981582 and ER-positive breast cancer risk and suggest a greater association of FGF1 rs250108 and RBFOX2 rs2051579 with ER-negative compared to ER-positive breast cancer. © 2012 Wiley Periodicals, Inc.